An interventional study of Prednisone and Placebo in Complex Regional Pain Syndromes and Distal Radius Fractures, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Complex Regional Pain Syndromes with a site in Canada — 4 open to participants now, 5 under way, none of them phase 3. Complex Regional Pain Syndromes · Canada.
Among the 17 studies in Complex Regional Pain Syndromes with a site in Canada, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, and was the 15th registered.
206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.
Browse Complex Regional Pain Syndromes studies →4 of the 17 studies in Complex Regional Pain Syndromes with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–70
McMaster University · Sites in Canada
Ages 18–70
Tracy Cupido · Sites in Canada
Ages 18–110 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 41 Complex Regional Pain Syndromes studies recruiting now, 19 (46%) set no upper age limit and 16 (39%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 152 interventional studies indexed under Complex Regional Pain Syndromes.
Median enrollment 22 across the 15 interventional studies, 111 across the 2 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 1 study filed under Complex Regional Pain Syndromes — fewer than ten, so there is no comparison to draw.
1 of the studies in Complex Regional Pain Syndromes with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06453447University of British ColumbiaPrednisone for CRPS in Distal Radius Fracture | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Complex Regional Pain Syndromes with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Wrist fractures are the most prevalent adult fracture. Complex regional pain syndrome (CRPS) is a common complication that can occur, leading to permanent disability and is costly to the patient and healthcare system. In addition, amidst the opioid epidemic, the risk of increased opioid use in patients with CRPS prompts the need to find viable treatment strategies. This study aims to evaluate an anti-inflammatory medication, prednisone, in the early treatment of CRPS. Patients with wrist fractures who undergo surgical treatment will be randomized to receiving placebo vs prednisone for 2 weeks. Clinical assessments in the follow up period will be compared.
Purpose:
Distal radius fractures are the most prevalent adult fracture, accounting for 17.5% of all fractures. Complex regional pain syndrome (CRPS) is a common complication that can occur in this population, with a reported incidence of up to 32%. CRPS can lead to permanent disability and is costly to the patient and to the healthcare system, with an estimated cumulative outpatient and pain prescription cost of $42,026 over 8 years after diagnosis. In addition, amidst the opioid epidemic, the risk of increased opioid use in patients with CRPS prompts the need to find viable treatment strategies.
While there have been various proposed treatment modalities, evidence from randomized studies is lacking. Several small studies (retrospective and prospective case series) have shown potential efficacy of glucocorticoids for the treatment of CRPS. To our knowledge, there are no randomized controlled trials that evaluate treatment of CRPS in distal radius fractures with glucocorticoids.
The purpose of this pilot study is to evaluate a short course of oral prednisone as potential treatment for patients identified as developing early signs of CRPS after sustaining a distal radius fracture that was treated operatively. We will examine feasibility metrics including patient recruitment rate, adherence to allocation and protocol, withdrawal from study, and follow-through, in order to inform design of a definitive clinical trial. We will also assess the resolution of CRPS, post-operative opioid use, and any adverse events in patients who sustain a distal radius fracture after receiving prednisone vs placebo for 2 weeks post-operatively, with 6 months follow up post injury.
Hypothesis:
We hypothesize that the proposed pilot trial will demonstrate feasibility of a future definitive trial.
In addition, we hypothesize that there will be higher rates of CRPS resolution, lower amounts of opioid consumption, and no increased adverse effects, and better clinical outcomes in patients who receive prednisone treatment compared to those who received placebo. However, formal hypothesis testing will not be performed for this pilot trial.
Justification:
Developing CRPS after sustaining a distal radius fracture can lead to devastating outcomes, including permanent disability, opioid dependency, and the inability to return to work. In addition, diagnosing CRPS can be a prolonged process due to the range of vague symptoms on presentation, which can lead to delay in treatment and worsening of outcomes. Patients with CRPS may require more follow-up and referrals, which further burdens the healthcare system.
The pathogenesis of CRPS is complex and not fully known; evidence suggests nervous system sensitisation, autonomic dysfunction, and inflammatory changes. There are numerous treatment options for CRPS, though little high-quality evidence supports their efficacy. These include but are not limited to oral anti-depressants, parenteral lidocaine and corticosteroids, surgical treatment with compressed nerve release, counselling, and occupational and physical therapy. Vitamin C has been proposed as effective prophylaxis for CRPS in distal radius fractures but data have been conflicting, with the most recent randomized controlled trial (RCT) in 2014 by Ekrol et al. showing no difference in functional outcomes or rate of CRPS in patients with distal radius fractures given Vitamin C versus placebo.
Given the prevalence of distal radius fractures in adults, a relatively high CRPS incidence in this population, and no established efficacious treatment options, more research is needed to determine evidence-based and effective treatment options for this destructive condition. Studies have identified that using glucocorticoids can potentially be effective and safe for treating patients with CRPS, possibly due to the anti-inflammatory properties of glucocorticoids. One retrospective study of patients undergoing surgery for terrible triad elbow (complex elbow fracture dislocation) injuries demonstrated improved elbow range of motion for patients receiving intraoperative dexamethasone and 6-day oral course of methylprednisolone compared to patients who did not, with no increased postoperative infection. Furthermore, the anti-inflammatory nature of glucocorticoids deserves investigation for its potential to decrease opioid consumption after distal radius surgery.
A variety of doses and duration of glucocorticoids have been used in studies to manage CRPS, with a recent review article by Kwak et al showing starting doses between 30 mg to 100 mg of prednisolone. Although glucocorticoids are known to be associated with adverse effects, most are only seen with long term therapy. In addition, studies have shown that a short-course of glucocorticoids (less than 3 to 4 weeks), irrespective of dose, do not require a tapering regimen and is not associated with increased risk of adrenal insufficiency. While osteoporosis and fracture non-union are known adverse events of long-term glucocorticoid use, this has not been demonstrated in literature for short-term use. Moreover, given the risk of non-union in distal radius fractures is exceedingly rare (0.2%), this calls for less concern for using glucocorticoids in this population.
Therefore, evaluating prednisone, a relatively cheap, accessible, and safe oral medication when used for a short duration, as an anti-inflammatory and potential early treatment agent for CRPS in distal radius fractures in this pilot study may have implications for the complication profile and functional outcome for this common fracture.
Research Design:
This will be a pilot double-blind randomized control trial in patients who sustain a distal radius fracture treated operatively with a volar locked plate and identified as at risk of developing CRPS. Follow up will be 6 months, involving 4 study visits that correspond to standard post-operative clinic visits.
Statistical Analysis:
A power analysis assuming incidence of 20% CRPS and absolute risk reduction (ARR) of 10% with prophylaxis yielded a sample size of 199 patients per arm, with 80% power and significance level (α) of 0.05 (performed using online sample size calculator at clincalc.com/stats/samplesize.aspx). Incidence and ARR were estimated based on previous RCTs assessing Vitamin C as prophylaxis for CRPS in distal radius fractures. We aim to recruit 10% for this pilot study, with 20 per arm (placebo vs prednisone), for a total of 40 patients.
The CONSORT guidelines for reporting of randomized pilot and feasibility trial will be followed for the analysis and reporting of results. An intention-to-treat analysis will be utilized.
Primary Outcomes: Descriptive statistics, reported as count and percentage, will be used to summarize the feasibility outcomes (95% CI). Table 2 presents the traffic lights criteria for each outcome of the pilot study. Green indicates feasible, red indicates not feasible, and yellow indicates likely feasible but will require adjustments to the protocol. (please see attached protocol)
Secondary and Tertiary Outcomes: Chi-square (or Fisher's Exact) test will be used to compare the proportion of CRPS between groups. Either Mann-Whitney U test or two-sample t test will be used for the other quantitative outcomes depending on the variable distribution. Multivariable regression analysis will be conducted to test for associations between the intervention and each outcome, controlling for differences in patient characteristics. All P values will be 2-sided and statistical significance will be set at P \< 0.05. For this pilot trial, formal hypothesis testing will not be performed as it is underpowered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is identified as at risk of developing CRPS with 2 or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg PO once daily for 14 days starting day of surgery
Drug: Prednisone
placebo tablet PO once daily for 14 days starting day of surgery
Drug: Placebo
40 mg PO once daily for 14 days starting day of surgery
Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
Proportion of patient recruitment
Percentage of patients approached for recruitment who consent to study participation
Time frame: 6 months
Proportion of patient adherence to treatment allocation and protocol - determined by patient self-reporting
Percentage of patients enrolled in the study who report to completing their 14-day course of treatment
Time frame: 6 months
Proportion of patients with missing data from secondary and tertiary outcomes
Percentage of enrolled patients who do not have complete secondary and tertiary outcome measures
Time frame: 6 months
Proportion of patient consent withdrawal from the study
Percentage of patients enrolled in the study who withdraw before completion of the study
Time frame: 6 months
Proportion of complete patient follow up at 6 months
Percentage of enrolled patients who complete all follow up visits
Time frame: 6 months
Resolution of CRPS
The treating surgeon or care team will determine whether patients continue to meet criteria for CRPS diagnosis based on the Budapest CRPS Criteria
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
Total opioid consumption
Total opioids consumed post-op converted to morphine milligram equivalents by assessing remaining hydromorphone tablets
Time frame: 2 weeks
Adverse effects
Adverse effects will be recorded. These can include but are not limited to mood changes, altered sleep, swelling of extremities, dizziness, headache, weight gain, elevated blood glucose, elevated blood pressure, upset stomach, gastrointestinal bleeding, wound complications, myopathy, infections, venous thromboembolism, hear failure, and adrenal insufficiency.
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
Visual analogue scale (VAS) pain score
Score out of 10 to monitor pain level
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
Centre of Epidemiologic Studies Depression (CES-D) score
to monitor for presence of depression
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
Short Form-36 item (SF-36) questionnaire
to measure patient reported quality of life
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
Passive wrist range of motion (ROM)
dorsiflexion, palmarflexion, supination, pronation, and finger to palm distance will be measured and recorded by the physiotherapist at each follow up visit
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
The disabilities of the arm, shoulder, and hand (DASH) questionnaire
to measure patient reported upper extremity disability and symptoms
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
The Brief Resiliency Scale (BRS) questionnaire
to assess patient reported ability to cope with stress
Time frame: 2 weeks, 6 weeks, 3 months, 6 months
Plan to share: No
Started Oct 2024 (actual). Primary completion is estimated for May 2027, 31 months after the start.
Of 66 non-industry interventional studies with no phase under Complex Regional Pain Syndromes, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 31 months is above that.
Counting every sponsor, half of 67 studies reached it within 24 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prednisone
Complex Regional Pain Syndromes →
University of British Columbia →